MedDataX Logo

A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.

NCT ID: NCT01727141

Last Updated: 2016-03-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

1042 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-11-30

Study Completion Date

2014-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A 12-week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation

NCT01712516

Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED PHASE3

Efficacy and Safety Study of QVA149 in COPD Patients

NCT02487446

Chronic Obstructive Pulmonary Disease
COMPLETED PHASE3

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

NCT02487498

Chronic Obstructive Pulmonary Disease
COMPLETED PHASE3

Efficacy and Safety of QVA149 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00570778

Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED PHASE2

A Study to Assess the Long-term Safety of QVA149

NCT01120717

Chronic Obstructive Pulmonary Disease
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

NOTE: Detailed Description: data not entered

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Obstructive Pulmonary Disease (COPD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

QVA149

27.5/12.5 ug twice daily (b.i.d.) via Single Dose Dry Powder Inhaler (SDDPI)

Group Type EXPERIMENTAL

QVA149

Intervention Type DRUG

QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI

QAB149

27.5 ug b.i.d.

Group Type ACTIVE_COMPARATOR

QAB149

Intervention Type DRUG

QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.

NVA237

12.5 ug b.i.d.

Group Type ACTIVE_COMPARATOR

NVA237

Intervention Type DRUG

NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.

Placebo

b.i.d

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

QVA149

QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI

Intervention Type DRUG

QAB149

QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.

Intervention Type DRUG

NVA237

NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.

Intervention Type DRUG

Placebo

Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients that have signed informed consent and are \>/= 40 years of age.
* Patients with stable COPD according to GOLD 2011.
* Patients with a post-bronchodilator FEV1 of \>/= 30% and \< 80% predicted and a post-bronchodilator FEV1/FVC \<0.70.
* Current or ex-smokers who have a smoking history of at least 10 pack years.
* Patients with an mMRC grade 2 or greater.

Exclusion Criteria

* Patients with Type I or uncontrolled Type II diabetes - Patients with a history of long QT syndrome or whose QTc measured at Visit 101 (Fridericia method) is prolonged (\>450 ms for males and females) and confirmed by a central assessor. (These patients should not be re-screened.)
* Patients who have a clinically significant ECG abnormality at Visit 101 or Visit 102. (These patients should not be re-screened.)
* Patients with a history of malignancy of any organ system, treated or untreated, within the last five years.
* Patients with narrow-angle glaucoma, BPH or bladder-neck obstruction or moderate-severe renal impairment or urinary retention.
* Patients who had a COPD exacerbation within 6 weeks prior to screening.
* Patients who have a respiratory tract infection within 4 weeks prior to screening.
* Patients requiring long term oxygen therapy prescribed for more than 12 hr per day.
* Patients with a history of asthma. 8. Patients with an onset of respiratory symptoms, including COPD diagnosis, prior to age 40 years.
* Patients with a blood eosinophil count of greater than 600 mm/3 during run-in.
* Patients with concomitant pulmonary disease.
* Patients with a diagnosis of alpha-1 anti-trypsin deficiency.
* Patients with active pulmonary tuberculosis.
* Patients in the active phase of a pulmonary rehabilitation programme.
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Novartis Investigative Site

Birmingham, Alabama, United States

Site Status

Novartis Investigative Site

Montgomery, Alabama, United States

Site Status

Novartis Investigative Site

Mesa, Arizona, United States

Site Status

Novartis Investigative Site

Phoenix, Arizona, United States

Site Status

Novartis Investigative Site

Fountain Valley, California, United States

Site Status

Novartis Investigative Site

Fullerton, California, United States

Site Status

Novartis Investigative Site

Huntington Beach, California, United States

Site Status

Novartis Investigative Site

Montclair, California, United States

Site Status

Novartis Investigative Site

Orange, California, United States

Site Status

Novartis Investigative Site

Orangevale, California, United States

Site Status

Novartis Investigative Site

Paramount, California, United States

Site Status

Novartis Investigative Site

Riverside, California, United States

Site Status

Novartis Investigative Site

Roseville, California, United States

Site Status

Novartis Investigative Site

Sacramento, California, United States

Site Status

Novartis Investigative Site

Sacramento, California, United States

Site Status

Novartis Investigative Site

Sacramento, California, United States

Site Status

Novartis Investigative Site

San Diego, California, United States

Site Status

Novartis Investigative Site

Torrance, California, United States

Site Status

Novartis Investigative Site

Wheat Ridge, Colorado, United States

Site Status

Novartis Investigative Site

Waterbury, Connecticut, United States

Site Status

Novartis Investigative Site

Chiefland, Florida, United States

Site Status

Novartis Investigative Site

Clearwater, Florida, United States

Site Status

Novartis Investigative Site

Lynn Haven, Florida, United States

Site Status

Novartis Investigative Site

Savannah, Georgia, United States

Site Status

Novartis Investigative Site

Meridian, Idaho, United States

Site Status

Novartis Investigative Site

O'Fallon, Illinois, United States

Site Status

Novartis Investigative Site

River Forest, Illinois, United States

Site Status

Novartis Investigative Site

Indianapolis, Indiana, United States

Site Status

Novartis Investigative Site

Columbia, Maryland, United States

Site Status

Novartis Investigative Site

Waltham, Massachusetts, United States

Site Status

Novartis Investigative Site

Ann Arbor, Michigan, United States

Site Status

Novartis Investigative Site

Edina, Minnesota, United States

Site Status

Novartis Investigative Site

Fridley, Minnesota, United States

Site Status

Novartis Investigative Site

Minneapolis, Minnesota, United States

Site Status

Novartis Investigative Site

Rochester, Minnesota, United States

Site Status

Novartis Investigative Site

Biloxi, Mississippi, United States

Site Status

Novartis Investigative Site

Saint Charles, Missouri, United States

Site Status

Novartis Investigative Site

St Louis, Missouri, United States

Site Status

Novartis Investigative Site

Omaha, Nebraska, United States

Site Status

Novartis Investigative Site

Papillion, Nebraska, United States

Site Status

Novartis Investigative Site

Las Vegas, Nevada, United States

Site Status

Novartis Investigative Site

Brooklyn, New York, United States

Site Status

Novartis Investigative Site

Brooklyn, New York, United States

Site Status

Novartis Investigative Site

Great Neck, New York, United States

Site Status

Novartis Investigative Site

Hendersonville, North Carolina, United States

Site Status

Novartis Investigative Site

Cincinnati, Ohio, United States

Site Status

Novartis Investigative Site

Cincinnati, Ohio, United States

Site Status

Novartis Investigative Site

Columbus, Ohio, United States

Site Status

Novartis Investigative Site

Columbus, Ohio, United States

Site Status

Novartis Investigative Site

Dublin, Ohio, United States

Site Status

Novartis Investigative Site

Marion, Ohio, United States

Site Status

Novartis Investigative Site

Medford, Oregon, United States

Site Status

Novartis Investigative Site

Pittsburgh, Pennsylvania, United States

Site Status

Novartis Investigative Site

Pittsburgh, Pennsylvania, United States

Site Status

Novartis Investigative Site

Pittsburgh, Pennsylvania, United States

Site Status

Novartis Investigative Site

Pittsburgh, Pennsylvania, United States

Site Status

Novartis Investigative Site

Tipton, Pennsylvania, United States

Site Status

Novartis Investigative Site

Anderson, South Carolina, United States

Site Status

Novartis Investigative Site

Greenville, South Carolina, United States

Site Status

Novartis Investigative Site

Spartanburg, South Carolina, United States

Site Status

Novartis Investigative Site

Union, South Carolina, United States

Site Status

Novartis Investigative Site

Chattanooga, Tennessee, United States

Site Status

Novartis Investigative Site

Boerne, Texas, United States

Site Status

Novartis Investigative Site

Dallas, Texas, United States

Site Status

Novartis Investigative Site

Dallas, Texas, United States

Site Status

Novartis Investigative Site

El Paso, Texas, United States

Site Status

Novartis Investigative Site

San Antonio, Texas, United States

Site Status

Novartis Investigative Site

South Burlington, Vermont, United States

Site Status

Novartis Investigative Site

Newport News, Virginia, United States

Site Status

Novartis Investigative Site

Richmond, Virginia, United States

Site Status

Novartis Investigative Site

Richmond, Virginia, United States

Site Status

Novartis Investigative Site

Seattle, Washington, United States

Site Status

Novartis Investigative Site

Tacoma, Washington, United States

Site Status

Novartis Investigative Site

Vancouver, British Columbia, Canada

Site Status

Novartis Investigative Site

Burlington, Ontario, Canada

Site Status

Novartis Investigative Site

Courtice, Ontario, Canada

Site Status

Novartis Investigative Site

Ottawa, Ontario, Canada

Site Status

Novartis Investigative Site

Toronto, Ontario, Canada

Site Status

Novartis Investigative Site

Toronto, Ontario, Canada

Site Status

Novartis Investigative Site

Toronto, Ontario, Canada

Site Status

Novartis Investigative Site

Windsor, Ontario, Canada

Site Status

Novartis Investigative Site

Gatineau, Quebec, Canada

Site Status

Novartis Investigative Site

Montreal, Quebec, Canada

Site Status

Novartis Investigative Site

Pointe-Claire, Quebec, Canada

Site Status

Novartis Investigative Site

Québec, Quebec, Canada

Site Status

Novartis Investigative Site

Québec, Quebec, Canada

Site Status

Novartis Investigative Site

Québec, Quebec, Canada

Site Status

Novartis Investigative Site

Saint Romuald, Quebec, Canada

Site Status

Novartis Investigative Site

Saint-Charles-Borromée, Quebec, Canada

Site Status

Novartis Investigative Site

Sainte-Foy, Quebec, Canada

Site Status

Novartis Investigative Site

Sainte-Foy, Quebec, Canada

Site Status

Novartis Investigative Site

Sherbrooke, Quebec, Canada

Site Status

Novartis Investigative Site

Trois-Rivières, Quebec, Canada

Site Status

Novartis Investigative Site

Victoriaville, Quebec, Canada

Site Status

Novartis Investigative Site

Bulacan, Philippines, Philippines

Site Status

Novartis Investigative Site

Manila, Philippines, Philippines

Site Status

Novartis Investigative Site

Quezon City, , Philippines

Site Status

Novartis Investigative Site

San Pablo City, Laguna, , Philippines

Site Status

Novartis Investigative Site

Lodz, , Poland

Site Status

Novartis Investigative Site

Tarnów, , Poland

Site Status

Novartis Investigative Site

Wroclaw, , Poland

Site Status

Novartis Investigative Site

Bucharest, District 1, Romania

Site Status

Novartis Investigative Site

Bucharest, District 1, Romania

Site Status

Novartis Investigative Site

Bucharest, District 3, Romania

Site Status

Novartis Investigative Site

Bucharest, District 3, Romania

Site Status

Novartis Investigative Site

Craiova, Dolj, Romania

Site Status

Novartis Investigative Site

Iași, Jud. Iasi, Romania

Site Status

Novartis Investigative Site

Arad, , Romania

Site Status

Novartis Investigative Site

Bucharest, , Romania

Site Status

Novartis Investigative Site

Deva, , Romania

Site Status

Novartis Investigative Site

Málaga, Andalusia, Spain

Site Status

Novartis Investigative Site

Palma de Mallorca, Balearic Islands, Spain

Site Status

Novartis Investigative Site

Santander, Cantabria, Spain

Site Status

Novartis Investigative Site

Ponferrada, Castille and León, Spain

Site Status

Novartis Investigative Site

Valladolid, Castille and León, Spain

Site Status

Novartis Investigative Site

Barcelona, Catalonia, Spain

Site Status

Novartis Investigative Site

Salt, Catalonia, Spain

Site Status

Novartis Investigative Site

Sant Boi de Llobregat, Catalonia, Spain

Site Status

Novartis Investigative Site

Cáceres, Extremadura, Spain

Site Status

Novartis Investigative Site

Mérida, Extremadura, Spain

Site Status

Novartis Investigative Site

Gijón, Principality of Asturias, Spain

Site Status

Novartis Investigative Site

Barakaldo, Vizcaya, Spain

Site Status

Novartis Investigative Site

Dnipropetrovsk, Ukraine, Ukraine

Site Status

Novartis Investigative Site

Kharkiv, Ukraine, Ukraine

Site Status

Novartis Investigative Site

Kharkiv, Ukraine, Ukraine

Site Status

Novartis Investigative Site

Dnipropetrovsk, , Ukraine

Site Status

Novartis Investigative Site

Donetsk, , Ukraine

Site Status

Novartis Investigative Site

Kharkiv, , Ukraine

Site Status

Novartis Investigative Site

Kiev, , Ukraine

Site Status

Novartis Investigative Site

Kiev, , Ukraine

Site Status

Novartis Investigative Site

Kyiv, , Ukraine

Site Status

Novartis Investigative Site

Kyiv, , Ukraine

Site Status

Novartis Investigative Site

Luhansk, , Ukraine

Site Status

Novartis Investigative Site

Lviv, , Ukraine

Site Status

Novartis Investigative Site

Poltava, , Ukraine

Site Status

Novartis Investigative Site

Vinnytsia, , Ukraine

Site Status

Novartis Investigative Site

Vinnytsia, , Ukraine

Site Status

Novartis Investigative Site

Zaporizhzhya, , Ukraine

Site Status

Novartis Investigative Site

Zaporizhzhya, , Ukraine

Site Status

Novartis Investigative Site

Zhytomyr, , Ukraine

Site Status

Novartis Investigative Site

Ho Chi Minh City, Vietnam, Vietnam

Site Status

Novartis Investigative Site

Hanoi, , Vietnam

Site Status

Novartis Investigative Site

Ho Chi Minh City, , Vietnam

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Philippines Poland Romania Spain Ukraine Vietnam

References

Explore related publications, articles, or registry entries linked to this study.

Mahler DA, Kerwin E, Murray L, Dembek C. The Impact of Twice-Daily Indacaterol/Glycopyrrolate on the Components of Health-Related Quality of Life and Dyspnea in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Chronic Obstr Pulm Dis. 2019 Oct 23;6(4):308-20. doi: 10.15326/jcopdf.6.4.2019.0131.

Reference Type DERIVED
PMID: 31539467 (View on PubMed)

Mahler DA, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C, Lloyd M, Patalano F, Banerji D. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015 Nov 1;192(9):1068-79. doi: 10.1164/rccm.201505-1048OC.

Reference Type DERIVED
PMID: 26177074 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CQVA149A2336

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) on Cardiac Function in COPD Patients
NCT02442206 COMPLETED PHASE4
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01202188 COMPLETED PHASE3
Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
NCT00558285 COMPLETED PHASE2
QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01315249 COMPLETED PHASE3
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01529632 COMPLETED PHASE3
A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149
NCT01709903 COMPLETED PHASE3
Comparison of Long-term Safety of the Combination Product QVA149A Against Placebo and Standard of Care Treatment in Chronic Obstructive Pulmonary Disease Patients With Moderate to Severe Airflow Limitation
NCT01610037 COMPLETED PHASE3
Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01294787 COMPLETED PHASE3
A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)
NCT02233543 COMPLETED PHASE4
The Effect of QVA149 on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01574651 COMPLETED PHASE3
Assessment of Switching From Salmeterol/Fluticasone to Indacaterol/Glycopyrronium in a symtomaticCOPD Patient Cohort
NCT02516592 COMPLETED PHASE4
Long Term Safety Study of NVA237 vs QAB149 in COPD Patients
NCT01697696 COMPLETED PHASE3
The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01490125 COMPLETED PHASE3
Efficacy and Safety of Four Doses of Glycopyrronium Bromide (NVA237) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), in Comparison to an Active Comparator Tiotropium
NCT00501852 COMPLETED PHASE2
Efficacy, Safety and Tolerability of the Co-administration of NVA237 Plus Indacaterol Once Daily Versus Indacaterol Once Daily in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT01604278 COMPLETED PHASE3
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
NCT01682863 COMPLETED PHASE3
An Exploratory Study, to Assess the Effect of Repeat-dose Inhaled Indacaterol Maleate (300 μg) on Dynamic and Static Lung Hyperinflation, Subjective Breathlessness and Health Status in Patients With Chronic Obstructive Pulmonary Disease(COPD)
NCT00636961 COMPLETED PHASE2
A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo
NCT01005901 COMPLETED PHASE3
Swiss studY for the Treatment of COPD Patients With the Free combiNation of indacatERol and GlYcopyrroniumbromide.
NCT01699685 COMPLETED PHASE3
Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
NCT00510510 COMPLETED PHASE2
A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
NCT01794780 COMPLETED PHASE4
Efficacy and Safety of NVA237 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01119950 COMPLETED PHASE2
Long Term Safety and Tolerability of QVA149 Versus Tiotropium in Japanese Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01285492 COMPLETED PHASE3
Effect of NVA237 on Exercise Endurance in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01154127 COMPLETED PHASE3
Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations
NCT01120691 COMPLETED PHASE3